C12N 2740/16034
Use of virus or viral component as vaccine
Official title: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2740/16034 (Use of virus or viral component as vaccine) appears on 400 US grants and 682 published applications in this corpus.
Search patents in C12N- Granted patents
- 400
- Published applications
- 682
- Assignees
- 371
- Inventors
- 1,149
- Latest grant
- 18 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1994 | 1 | 0 |
| 1995 | 3 | 0 |
| 1996 | 0 | 0 |
| 1997 | 6 | 0 |
| 1998 | 8 | 0 |
| 1999 | 3 | 0 |
| 2000 | 5 | 0 |
| 2001 | 2 | 3 |
| 2002 | 10 | 15 |
| 2003 | 6 | 16 |
| 2004 | 3 | 28 |
| 2005 | 5 | 20 |
| 2006 | 10 | 22 |
| 2007 | 4 | 15 |
| 2008 | 4 | 21 |
| 2009 | 11 | 27 |
| 2010 | 12 | 27 |
| 2011 | 11 | 24 |
| 2012 | 13 | 29 |
| 2013 | 7 | 27 |
| 2014 | 17 | 28 |
| 2015 | 26 | 44 |
| 2016 | 18 | 48 |
| 2017 | 23 | 27 |
| 2018 | 35 | 31 |
| 2019 | 28 | 34 |
| 2020 | 27 | 28 |
| 2021 | 26 | 27 |
| 2022 | 14 | 30 |
| 2023 | 23 | 36 |
| 2024 | 16 | 30 |
| 2025 | 10 | 27 |
| 2026 | 13 | 18 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- HIV immunotherapy with no pre-immunization step18 Aug 2026US 12,709,753 B2American Gene Technologies International Inc.
- Compositions, devices and methods for inducing immune responses to infectious agents16 Jun 2026US 12,653,888 B2Sigilon Therapeutics, Inc.
- Nucleic acid nanostructure platform for programming immune stimulation2 Jun 2026US 12,642,850 B2Massachusetts Institute of Technology
- Infectious disease antigens and vaccines5 May 2026US 12,616,746 B2Seattle Project Corp.
- Method of inducing an HIV-1-specific immune response using a chimpanzee adenovirus vector encoding an hivacat t-cell immunogen and TLR7 agonist28 Apr 2026US 12,611,453 B2Gilead Sciences, Inc.
- Hiv immunogenic polypeptides and vaccines and uses thereof24 Sep 2026US 2026/0284175 A1Gilead Sciences, Inc.
- Antigen-specific physiologic dendritic cells for vaccination17 Sep 2026US 2026/0273045 A1Emory University
- Nanoparticle compositions and uses thereof for reactivation of latent hiv27 Aug 2026US 2026/0248880 A1The Trustees of the University of Pennsylvania
- Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response27 Aug 2026US 2026/0248912 A1Barinthus Biotherapeutics North America, Inc.
- A Fusion Protein and a Particulate Antigen Containing the Same27 Aug 2026US 2026/0250328 A1Xiamen Innovax Biotech Co., Ltd.
Most cited
By later US patents
- Immunizing compositions comprising nucleic acids encoding the HIV-1 matrix protein myristate binding site1,449US 7,718,180 B22010
- Genetic immunization277US 5,593,972 AThe Trustees of the University of Pennsylvania · 1997
- Genetic immunization137US 5,817,637 AThe Trustees of the University of Pennsylvania · 1998
- Genetic immunization117US 5,830,876 AThe Trustees of the University of Pennsylvania · 1998
- Adenovirus vector with multiple expression cassettes110US 6,544,780 B1GenPhar, Inc. · 2003